Tradestie Institutional Equity Comparison Engine

MBIO vs ABVE โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-17 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

MBIO Overall Edge

MBIO Captures Institutional Edge (2โ€“1 Pillars ยท 6โ€“2 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Mustang Bio, Inc. (MBIO) driven by superior Growth & Margin, Momentum & Technical while ABVE counters with relative strength in Options & Structure. Fundamentally, MBIO trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus ABVE at N/M Forward P/E and -23.2% operating margin (-45.0% YoY). In options structure, MBIO sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against ABVE sits in UNCLASSIFIED (8th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
MBIO N/M vs ABVE N/M Fwd P/E
Growth & Margin Winner MBIO
Op Margin 0.0% vs -23.2% ยท YoY +0.0% vs -45.0%
Momentum & Technical Winner MBIO
1Y -68.4% vs -90.2% ยท 52W Pos 3% vs 0%
Options & Structure Winner ABVE
UNCLASSIFIED (N/A IV) vs UNCLASSIFIED (8th %ile IV)
MBIO NASDAQ
Mustang Bio, Inc.
Pharmaceutical Preparations
$0.39
-2.46% 1D
Market Cap $3.2M
1M Return +3.22%
1Y Return -68.44%
Forward P/E N/M
Unified AI Score
42.9 / 100 HOLD
Tech 40.0 Fund 49.0 Flow 50.0 Mom 70.0
ABVE NASDAQ
Above Food Ingredients Inc. Common Stock
Food And Kindred Products
$0.11
-80.57% 1D
Market Cap $30.0M
1M Return -79.18%
1Y Return -90.17%
Forward P/E N/M
Unified AI Score
39.8 / 100 SELL
Tech 40.0 Fund 47.0 Flow 57.0 Mom 40.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: MBIO -68.44% ABVE -90.17% Spread: +57.8 pp (MBIO Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
MBIO TTM Op. Margin: 0.0% ABVE TTM Op. Margin: -23.2%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on MBIO vs ABVE. Trailing 12-month operating profitability (MBIO 0.0% vs ABVE -23.2%) and valuation multiples (MBIO N/M vs ABVE N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: MBIO (6) vs ABVE (2)
Institutional Metric MBIO ABVE Criterion Row Winner
Market Capitalization Scale $3.2M $30.0M Larger Scale ABVE
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth +0.0% -45.0% Higher Growth MBIO
Operating Margin (TTM) Profitability 0.0% -23.2% Higher Margin MBIO
Net Profit Margin Profitability 0.0% -23.4% Higher Margin MBIO
Return on Equity (ROE) Capital Efficiency -43.1% 0.0% Higher ROE ABVE
52-Week Range Position Momentum 3% ($0โ€“$1) 0% ($0โ€“$7) Stronger Trend MBIO
Beta / 30D Volatility Risk Regime 0.68ฮฒ ยท 87% Vol 4.10ฮฒ ยท 310% Vol Lower Realized Risk MBIO
Unified Institutional Score Composite Signal 42.9 / 100 (HOLD) 39.8 / 100 (SELL) Higher Composite MBIO

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full MBIO vs ABVE Buy Guide
MBIO UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live MBIO Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
ABVE UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 8th %ile
IV Regime Compressed (<25th %ile)
Live ABVE Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither MBIO nor ABVE registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.